Pixalate Releases Q2 2024 Global Mobile Device Market Share Report: Apple iPhone Leads Globally (51%), Followed by Samsung, Huawei, & Xiaomi
21 août 2024 17h14 HE
|
Pixalate
London, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Pixalate, the market-leading fraud protection, privacy, and compliance analytics platform for Connected TV (CTV) and Mobile Advertising, today released the...
Navitas Powers Expanded Samsung Galaxy Smartphone Portfolio
05 août 2024 08h30 HE
|
Navitas Semiconductor Corporation
TORRANCE, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Navitas Semiconductor (Nasdaq: NVTS), the industry leader in next-generation GaNFast™ gallium nitride (GaN) and GeneSiC™ silicon carbide (SiC)...
Pixalate Releases Top 100 Connected TV (CTV) Bundle ID Rankings For Global Open Programmatic Ad Spend on Roku, Amazon Fire TV, Samsung Smart TV, and Apple TV in June 2024
17 juil. 2024 13h20 HE
|
Pixalate Inc.
LONDON, July 17, 2024 (GLOBE NEWSWIRE) -- Pixalate, the market-leading fraud protection, privacy, and compliance analytics platform for Connected TV (CTV) and Mobile Advertising, today released the...
Standard Bots Secures $63M in Funding to Propel American Manufacturing Forward with AI-Driven Robotics
12 juil. 2024 12h00 HE
|
Standard Bots
Standard Bots secures $63M to advance US manufacturing with AI-driven robotics, backed by General Catalyst, Amazon, and Samsung, serving clients like NASA.
Samsung Bioepis Releases Third Quarter 2024 US Biosimilar Market Report
11 juil. 2024 08h00 HE
|
Samsung Bioepis
Samsung Bioepis Releases Third Quarter 2024 US Biosimilar Market Report
FDA Approves PYZCHIVA® (ustekinumab-ttwe), Samsung Bioepis’ Biosimilar to Stelara
01 juil. 2024 02h03 HE
|
Samsung Bioepis
PYZCHIVA becomes Samsung Bioepis’ seventh biosimilar and fourth immunology biosimilar approved by the FDAPYZCHIVA’s licensing period will begin on February 22, 2025, in the United States, based on the...
Samsung Bioepis Releases 2024 Sustainability Report, Highlighting Progress in Accessibility and R&D Innovation
25 juin 2024 09h00 HE
|
Samsung Bioepis
Samsung Bioepis Releases 2024 Sustainability Report, Highlighting Progress in Accessibility and R&D Innovation
Samsung Bioepis Presents Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimilar), at the European Hematology Association (EHA) Congress 2024
14 juin 2024 03h00 HE
|
Samsung Bioepis
Samsung Bioepis Presents Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimilar), at the European Hematology Association (EHA) Congre
Pixalate Releases Q1 2024 Global Mobile Device Market Share Report: Apple Ranks No. 1 with 49% Market Share, Huawei Rises to No. 4
21 mai 2024 14h32 HE
|
Pixalate Inc.
LONDON, May 21, 2024 (GLOBE NEWSWIRE) -- Pixalate, the market-leading fraud protection, privacy, and compliance analytics platform for Connected TV (CTV) and Mobile Advertising, today released the...
Wearable Devices Invited to Present its Gesture Control Technology to Samsung's Senior Management in South Korea
02 mai 2024 08h45 HE
|
Wearable Devices Ltd.
YOKNEAM ILLIT, ISRAEL, May 02, 2024 (GLOBE NEWSWIRE) -- Wearable Devices Ltd. (the “Company” or “Wearable Devices”) (Nasdaq: WLDS, WLDSW), a technology growth company specializing in artificial...